Talk:Aripiprazole: Difference between revisions

>Blackhole
removed decree / formating
>CutieKiley
Removed vandalism
 
(63 intermediate revisions by 3 users not shown)
Line 9: Line 9:


==Chemistry==
==Chemistry==
Aripiprazole is a synthetic substance of the quinolinone class and is structurally distinct from other atypical antipsychotics. Its molecular formula is C_{23}H_{27}Cl_{2}N_{3}O_{2}, and it has a unique mechanism of action as a dopamine-serotonin system stabilizer.  
Aripiprazole is a synthetic substance of the quinolinone class and is structurally distinct from other atypical antipsychotics. Its molecular formula is C<sub>23</sub>H<sub>27</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>2</sub>, and it has a unique mechanism of action as a dopamine-serotonin system stabilizer.  


==Pharmacology==
==Pharmacology==
Line 33: Line 33:


}}
}}
{{effects/cognitive|
|{{effects/cognitive|
Cognitive effects of Aripiprazole can include:
Cognitive effects of Aripiprazole can include:


Line 45: Line 45:
* '''[[Effect::Insomnia]]''' - Difficulty falling or staying asleep in some individuals.
* '''[[Effect::Insomnia]]''' - Difficulty falling or staying asleep in some individuals.
* '''[[Effect::Memory suppression|Short-term memory suppression]]''' - In rare cases, may affect short-term memory.
* '''[[Effect::Memory suppression|Short-term memory suppression]]''' - In rare cases, may affect short-term memory.
}}
}}
{{effects/auditory|
Auditory effects are typically therapeutic in nature, reducing symptoms in those with auditory hallucinations due to mental health conditions:
* '''[[Effect::Decreased auditory hallucinations]]''' - Often effective in reducing or eliminating auditory hallucinations in schizophrenia or other psychotic disorders.
}}
}}
{{effects/visual|
The visual effects of Aripiprazole are comparable to that of certain aspects [[deliriants]] and [[dissociatives]].


*'''[[Effect::Acuity suppression]]'''
*'''[[Effect::Double vision]]''' - [[Double vision]] is a common side effect, especially at higher doses and can cause long-term problems with vision depending on the duration of use.
*'''[[Effect::Shadow people]]''' - This effect is rarely seen with therapeutic use.
}}
==Experience reports==
==Experience reports==
There are a limited number of experience reports for Aripiprazole given its medical usage, but some can be found in the [[experience index]] and on external platforms like Erowid.
There are a limited number of experience reports for Aripiprazole given its medical usage, but some can be found in the [[experience index]] and on external platforms like Erowid.
Line 86: Line 73:
==External links==
==External links==
*[https://en.wikipedia.org/wiki/Aripiprazole Aripiprazole (Wikipedia)]
*[https://en.wikipedia.org/wiki/Aripiprazole Aripiprazole (Wikipedia)]
*[https://www.erowid.org/pharms/aripiprazole/ Aripiprazole (Erowid Vault)]
*[https://isomerdesign.com/pihkal/explore/9511 Aripiprazole (Isomer Design)]
*[https://go.drugbank.com/drugs/DB01238 Aripiprazole (DrugBank)]
*[https://www.drugs.com/aripiprazole.html Aripiprazole (Drugs.com)]


==References==
==References==
<references />
<references />
The 2016 [[NICE]] guidance for treating psychosis and schizophrenia in children and young people recommended aripiprazole as a second line treatment after [[risperidone]] for people between 15 and 17 who are having an acute exacerbation or recurrence of psychosis or schizophrenia.<ref>{{cite web |title=Psychosis and schizophrenia in children and young people: recognition and management {{!}} Guidance and guidelines {{!}} NICE |url=https://www.nice.org.uk/guidance/cg155/chapter/Recommendations |publisher=NICE |date=October 2016}}</ref> A 2014 NICE review of the depot formulation of the drug found that it might have a role in treatment as an alternative to other depot formulations of second generation antipsychotics for people who have trouble taking medication as directed or who prefer it.<ref>{{cite web |title=Schizophrenia: aripiprazole prolonged-release suspension for injection {{!}} Guidance and guidelines {{!}} NICE |url=https://www.nice.org.uk/advice/esnm39/chapter/Key-points-from-the-evidence |publisher=NICE |date=24 July 2013}}</ref>


[[Category:Psychoactive substance]][[Category:Proofread]][[Category:Approval]]
[[Category:Psychoactive substance]][[Category:Proofread]][[Category:Approval]]
Return to "Aripiprazole" page.